스페로이드 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 방법별, 공급원별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Spheroids Market Growth & Trends:

The global spheroids market size is expected to reach USD 2.46 billion by 2030 and is anticipated to grow at a CAGR of 22.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has gained significant traction due to the growing demand for advanced 3D cell culture models that offer more physiologically relevant conditions than traditional 2D cultures. Spheroids, which better mimic the cellular architecture, nutrient gradients, and microenvironment of tissues in vivo, are increasingly used in drug screening, disease modeling, toxicology testing, and regenerative medicine. Their application spans a wide range of therapeutic areas, including oncology, neurology, and metabolic diseases, as researchers and pharmaceutical companies prioritize more accurate preclinical models to improve drug development success rates and reduce late-stage failures.

Another major driver is the integration of spheroids into high-throughput screening (HTS) systems, enabling pharmaceutical and biotechnology companies to evaluate large compound libraries with greater predictive value. The market is also fueled by developing novel tools and technologies such as low-attachment plates, hanging drop systems, and microfluidic platforms that simplify spheroid generation and improve reproducibility. In addition, increased funding from government agencies and private investors has supported the expansion of 3D culture research in academic and commercial settings.

The COVID-19 pandemic further accelerated the adoption of spheroid models, particularly in virology and immunology research. As researchers sought models that more closely represented human tissues, spheroids proved valuable for studying SARS-CoV-2 infection mechanisms, host immune responses, and antiviral drug efficacy. The pandemic highlighted the limitations of conventional 2D cultures and animal models in rapidly understanding complex diseases, leading to increased investment in 3D culture technologies, including spheroids. This shift also supported long-term market growth as laboratories increasingly adopted advanced culture systems to future-proof research infrastructure.

Post-pandemic, the momentum around spheroids has continued, driven by a global push toward more ethical and efficient preclinical testing strategies. Regulatory agencies and research institutions increasingly recognize the value of spheroids and other 3D models in reducing animal testing while improving translational outcomes. Furthermore, the rise of personalized medicine and the use of patient-derived cells to form disease-specific spheroids are opening new opportunities for customized drug development and therapeutic testing. Together, these factors are shaping a robust outlook for the market in the years ahead.

Spheroids Market Report Highlights:

• The multicellular tumor spheroids (MCTS) segment accounted for the largest revenue share of 28.91% in 2024 and is expected to have the fastest growth rate over the forecast period. MCTS closely replicates the in vivo tumor microenvironment, enabling more accurate cancer research and drug screening. Their ability to model tumor heterogeneity and drug resistance drives their adoption in oncology-focused studies.
• The hanging drop method segment accounted for the largest revenue share of 31.34% in 2024 and is expected to have the fastest growth rate over the forecast period. This simple and cost-effective technique facilitates uniform spheroid formation without scaffolds, ideal for controlled experimental setups. Its ease of use and compatibility with high-throughput systems support widespread research adoption.
• The cell line segment accounted for a larger revenue share of 56.64% in 2024. Cell lines are a major market driver because they provide a standardized, reproducible, and cost-effective resource for generating 3D spheroid models across a wide range of research applications.
• The regenerative medicine segment is expected to witness the highest CAGR over the forecast period. Spheroids enhance tissue engineering by promoting cell-cell interactions and mimicking native tissue structures. Their role in developing functional tissue constructs makes them essential in regenerative therapies.
• The biotechnology and pharmaceutical industries segment accounted for the largest revenue share of 46.33% in 2024. These industries utilize spheroids for predictive toxicology, efficacy screening, and disease modeling. The demand for human-relevant, scalable 3D models drives their integration into R&D pipelines.
• North America dominated the market due to its well-established regulatory frameworks and healthcare infrastructure. These facilitate the clinical translation and adoption of spheroid-based products, further propelling market growth.
• Thermo Fisher Scientific Inc., Corning Incorporated, Merck KGaA, Lonza, InSphero AG, Greiner Bio-One International GmbH, 3D Biotek LLC, CN Bio Innovations, Kuraray Co., Ltd., and Tecan Group Ltd. are some of the market players operating in the market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Method
  • 1.1.3. Source
  • 1.1.4. Application
  • 1.1.5. End Use
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Spheroids Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High adoption of spheroids in drug discovery
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Rising demand for tissue engineering & organ transplantation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Challenges associated with 3D cell culturing
    • 3.2.2.2. Ethical issues associated with spheroid cultures
• 3.3. Spheroids Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Spheroids Market: Type Movement Analysis
• 4.3. Global Spheroids Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Multicellular tumor spheroids (MCTS)
  • 4.4.1. MCTS market estimates and forecast, 2018 - 2030
• 4.5. Neurospheres
  • 4.5.1. Neurospheres market estimates and forecast, 2018 - 2030
• 4.6. Mammospheres
  • 4.6.1. Mammospheres market estimates and forecast, 2018 - 2030
• 4.7. Hepatospheres
  • 4.7.1. Hepatospheres market estimates and forecast, 2018 - 2030
• 4.8. Embryoid bodies
  • 4.8.1. Embryoid bodies market estimates and forecast, 2018 - 2030

Chapter 5. Method Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Spheroids Market: Method Movement Analysis
• 5.3. Global Spheroids Market Size & Trend Analysis, by Method, 2018 to 2030 (USD Million)
• 5.4. Micropatterned Plates
  • 5.4.1. Micropatterned plates market estimates and forecast, 2018 - 2030
• 5.5. Low Cell Attachment Plates
  • 5.5.1. Low cell attachment plates market estimates and forecast, 2018 - 2030
• 5.6. Hanging Drop Method
  • 5.6.1. Hanging drop method market estimates and forecast, 2018 - 2030
• 5.7. Others
  • 5.7.1. Other methods market estimates and forecast, 2018 - 2030

Chapter 6. Source Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Spheroids Market: Source Movement Analysis
• 6.3. Global Spheroids Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
• 6.4. Cell Line
  • 6.4.1. Cell line market estimates and forecast, 2018 - 2030
• 6.5. Primary Cell
  • 6.5.1. Primary cell market estimates and forecast, 2018 - 2030
• 6.6. iPSCs Derived Cells
  • 6.6.1. iPSCs derived cells market estimates and forecast, 2018 - 2030

Chapter 7. End Use Business Analysis

• 7.1. Segment Dashboard
• 7.2. Global Spheroids Market: End Use Movement Analysis
• 7.3. Global Spheroids Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Biotechnology and Pharmaceutical Industries
  • 7.4.1. Biotechnology and pharmaceutical industries market estimates and forecast 2018 to 2030, (USD million)
• 7.5. Academic & Research Institutes
  • 7.5.1. Academic & research institutes market estimates and forecast 2018 to 2030, (USD Million)
• 7.6. Hospitals and Diagnostic Centers
  • 7.6.1. Hospitals and diagnostic centers market estimates and forecast 2018 to 2030, (USD million)

Chapter 8. Application Business Analysis

• 8.1. Segment Dashboard
• 8.2. Global Spheroids Market: Application Movement Analysis
• 8.3. Global Spheroids Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 8.4. Developmental Biology
  • 8.4.1. Developmental biology market estimates and forecast 2018 to 2030, (USD million)
• 8.5. Personalized Medicine
  • 8.5.1. Personalized medicine market estimates and forecast 2018 to 2030, (USD Million)
• 8.6. Regenerative Medicine
  • 8.6.1. Regenerative medicine market estimates and forecast 2018 to 2030, (USD million)
• 8.7. Disease Pathology Studies
  • 8.7.1. Disease pathology studies market estimates and forecast 2018 to 2030, (USD Million)
• 8.8. Drug Toxicity & Efficacy Testing
  • 8.8.1. Drug toxicity & efficacy testing market estimates and forecast 2018 to 2030, (USD Million)

Chapter 9. Regional Business Analysis, by Country, Type, Method, Source, Application, & End Use

• 9.1. Segment Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 9.3. North America
  • 9.3.1. North America market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. U.S. Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Canada Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Competitive Scenario
    • 9.3.4.4. Mexico Market estimates and forecast, 2018 - 2030 (USD Billion)
• 9.4. Europe
  • 9.4.1. Europe Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. UK Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. Germany Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. France Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Italy Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Spain Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Denmark Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Target Disease Prevalence
    • 9.4.8.3. Competitive Scenario
    • 9.4.8.4. Sweden Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Target Disease Prevalence
    • 9.4.9.3. Competitive Scenario
    • 9.4.9.4. Norway Market estimates and forecast, 2018 - 2030 (USD Billion)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.5.2. China
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. China Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.5.3. Japan
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. Japan Market estimates and forecast, 2018 - 2030 (Volume, Thousand)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Competitive Scenario
    • 9.5.4.4. India Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.5.5. Australia
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Competitive Scenario
    • 9.5.5.4. Australia Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Competitive Scenario
    • 9.5.6.4. Thailand Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.5.7. South Korea
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Competitive Scenario
    • 9.5.7.4. South Korea Market estimates and forecast, 2018 - 2030 (USD Billion)
• 9.6. Latin America
  • 9.6.1. Latin America Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Brazil Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Competitive Scenario
    • 9.6.3.4. Argentina Market estimates and forecast, 2018 - 2030 (USD Billion)
• 9.7. MEA
  • 9.7.1. MEA Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Competitive Scenario
    • 9.7.2.4. Saudi Arabia Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.7.3. South Africa
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Competitive Scenario
    • 9.7.3.4. South Africa Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Target Disease Prevalence
    • 9.7.4.3. Competitive Scenario
    • 9.7.4.4. UAE Market estimates and forecast, 2018 - 2030 (USD Billion)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Target Disease Prevalence
    • 9.7.5.3. Competitive Scenario
    • 9.7.5.4. Kuwait Market estimates and forecast, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Thermo Fisher Scientific, Inc.
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Merck KGaA
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Lonza
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. CN Bio Innovations
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. 3D Biotek LLC
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Kuraray Co., Ltd.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Tecan Group Ltd.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Corning Incorporated
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Greiner Bio-One
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. InSphero
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives